Navigation Links
WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

BOTHELL, Wash., March 1, 2011 /PRNewswire/ -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at Overlake Hospital Medical Center in Bellevue and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths.  Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.Warfarin is prescribed to 2 million patients in the U.S. annually and approximately 20 million Americans use the drug in total.  Warfarin is difficult to dose as patients respond to it differently according to their genetic makeup -- too much warfarin can result in severe bleeding, and too little can cause clot formation and increased risk of stroke.  In the past, warfarin dosing relied on trial-and-error, which exposed patients to serious medical risks.  Warfarin is the second most frequent cause of drug-related emergency room visits.  

"Safeguarding the health of our citizens is always a top priority of government," said Rogers Weed, Director of the Washington State Department of Commerce. "The WARFARIN Study aims to demonstrate that using genetic testing for warfarin dosing can improve patients' overall health, save lives and lower healthcare costs here in Washington as well as nationwide. As a leader in advancing genetically-based medical practice, Washington is proud that a local company and one of our state's premier hospitals are taking the lead in th
'/>"/>

SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. Pivotal Study Validates Roches cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
3. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
4. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
5. Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. New test to study proteins involved in neurodegenerative diseases
8. A new model for studying Parkinsons
9. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
10. Columbia University researchers use nanoscale transistors to study single-molecule interactions
11. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... from roadside bombs to freeway crashes. Traumatic injury, the leading ... overwhelms the body,s natural blood-clotting process. In an effort ... Lavik, a new Case Western Reserve University biomedical engineering professor, ... platelets that show promise in halting internal and external bleeding. ...
... , Nursing Care at Hahnemann among the Best ... University Hospital proudly announces it has been granted Magnet(R) recognition ... Magnet(R) is one of the highest levels of recognition a ... the five percent of hospitals in the country that have ...
... , , , , ... of the world,s leading research and advisory firms for ... from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag,s Stelara and Abbott,s ... the biologics share in 2012 in the drug market ...
Cached Biology Technology:Researchers take the inside route to halt bleeding 2Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... could help deliver drugs and shape the growth of ... supermodel lips. But by mating collagen with a molecular ... some important medical advances. The researchers have found a ... for better infection-fighting bandages and a treatment to block ...
... bit of biology called site-specific recombination, DNA can travel inside ... of grafting surgery that allows it to insert its chromosome ... important because mobile DNA can carry genes that cause drug ... result in certain leukemias or other cancers. , But what ...
... blindness in older adults, yet researchers are still in ... this incurable disease. , But new insight from University ... between rhesus monkeys with macular degeneration and humans could ... when severe vision loss could still be stopped. , ...
Cached Biology News:Unusual antibiotics show promise against deadly 'superbugs' 2Unusual antibiotics show promise against deadly 'superbugs' 3Brown-Harvard team solves mobile DNA's surgical sleight-of-hand 2Genetic links could unlock clues to leading cause of blindness 2Genetic links could unlock clues to leading cause of blindness 3
... Labeling Kit with CyScribe GFX Purification ... and purification of Cy3- and Cy5-labeled ... complete cDNA labeling and purification.Flexible and ... performing labeling reactions with either Cy3- ...
... CyScribe Post-Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
UV-NIR light source for USB2000, HR4000, HR2000+...
Biology Products: